The SPDR S&P Biotech ETF (XBI) closed at $168.39 on August 27, 2026, declining 0.44% over the prior 24-hour period. The modest pullback extended a slight weekly retreat, with the fund down 0.70% over the past seven days.
Despite the recent softness, XBI has posted a notable recovery over the broader monthly window. The ETF gained 11.79% over the past 30 days, reflecting a sustained period of strength in the biotech sector heading into late August.
The fund tracks an equal-weighted index of biotechnology companies listed on U.S. exchanges, making it a widely followed barometer of sentiment across the biotech space. Equal weighting gives smaller-cap names meaningful influence on overall performance.
Market capitalization data for XBI was not available as of this report. The gap between the fund's strong monthly performance and its mild short-term dip suggests some consolidation following the recent run-up.
